Results 11 to 20 of about 2,402,251 (269)
Advances in iron chelation therapy: transitioning to a new oral formulation
Drugs in Context, 2017 Iron overload is a concern for patients who require repeated red-blood-cell transfusions due to conditions such as sickle cell disease, thalassemia, or myelodysplastic syndromes.
Nirmish R Shah
doaj +2 more sources
EDTA chelation therapy for cardiovascular disease: a systematic review [PDF]
BMC Cardiovascular Disorders, 2005 Background Numerous practitioners of both conventional and complementary and alternative medicine throughout North America and Europe claim that chelation therapy with EDTA is an effective means to both control and treat cardiovascular disease.
Wu Ping, Seely Dugald MR, Mills Edward J
doaj +5 more sources
Will Short Peptides Revolutionize Chelation Therapy? [PDF]
CHIMIA, 2022 It will soon be twenty years since the last chelating agent was clinically approved to be used against toxic metals. Even though metal poisoning has been known to humankind for centuries, only about a dozen compounds, all of which are small molecules ...
Michal S. Shoshan
doaj +2 more sources
Iron Chelation Therapy in Myelodysplastic Syndromes [PDF]
Advances in Hematology, 2010 Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload.
Emanuela Messa +2 more
doaj +2 more sources
Chelator-facilitated removal of iron from transferrin: Relevance to combined chelation therapy [PDF]
, 2008 Current iron chelation therapy consists primarily of DFO (desferrioxamine), which has to be administered via intravenous infusion, together with deferiprone and deferasirox, which are orally-active chelators.
Evans, PJ +3 more
core +8 more sources
Iron overload is a serious complication associated with transfusion-dependent anemias and anemias characterized by ineffective erythropoiesis. Iron accumulation is toxic to many tissues, causing heart failure, cirrhosis, liver cancer, growth retardation, and multiple endocrine abnormalities.Chelation therapy aims to balance the rate of iron ...
Cappellini, Maria Domenica +3 more
openaire +3 more sources
Combined iron chelation therapy
Annals of the New York Academy of Sciences, 2010 Patients with thalassemia major accumulate body iron over time as a consequence of continuous red blood cell transfusions which cause hepatic, endocrine, and cardiac complications. Despite the availability of three iron chelators, some patients fail to respond adequately to monotherapy with any of them. Combination therapy, consisting in the use of two
Galanello Renzo +5 more
openaire +3 more sources
Chelation therapy and autism [PDF]
BMJ, 2006 EDITOR—More children are being diagnosed as having autism, and there are currently no treatments based on aetiology.1 Consequently, a number of controversial, unproved, alternative treatments have arisen. The recent death of an autistic child after a medication error with intravenous chelation therapy has brought one purported aetiology based treatment
Yashwant, Sinha +2 more
openaire +2 more sources
Annals of the New York Academy of Sciences, 2023 Abstract Combination chelation therapies are considered in transfusion‐dependent thalassemia patients for whom monotherapy regimens have failed to achieve iron balance or intensification of iron chelation therapy is required for the rapid reduction of excess iron to avoid permanent organ damage.
openaire +2 more sources
Journal of Internal Medicine, 1997 Desferrioxamine (DFX) remains the most effective and safe iron chelator for treatment of patients with transfusional iron overload. It is usually given by intermittent subcutaneous infusions for 8–12 h on 4–6 days weekly using a battery‐driven pump. Disposable balloon infusers provide a suitable method of giving continuous subcutaneous infusions with ...
A V, Hoffbrand, B, Wonke
openaire +2 more sources